New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
08:44 EDTMGNXMacroGenics reports milestone in DART program triggers $20M in payments
MacroGenics announced that Servier, France's largest privately-held pharmaceutical company, has exercised its exclusive option to develop and commercialize MGD006, a DART-based product candidate developed by MacroGenics. Servier will gain exclusive development and commercial rights in all countries outside of the U.S., Canada, Mexico, Japan, South Korea and India. In those countries, MacroGenics will retain development and commercialization rights. As a result of the exercise, MacroGenics will receive a $15M payment from Servier. In addition, the Investigational New Drug application for MGD006 has cleared the 30 day review period by the U.S. Food and Drug Administration, triggering an additional $5M payment to MacroGenics by Servier.
News For MGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 6, 2015
12:13 EDTMGNXMacroGenics to host research and development day
Subscribe for More Information
07:23 EDTMGNXAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
October 5, 2015
09:15 EDTMGNXMacroGenics has reached 'intriguing entry point,' says Roth Capital
Noting that MacroGenics' stock has tumbled nearly 40% over the past three months, Roth Capital says that the decline has significantly discounted the differentiation of the company's cancer treatment, MGA271, and offers an intriguing entry point for long-term investors focused on MacroGenics' DART-platform. Roth keeps a $45 price target and Buy rating on the shares.
October 1, 2015
07:31 EDTMGNXLeerink to hold a roundtable
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use